Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - Updated overview and meta-analyses of randomized trials

Journal of Hypertension

Volumn 34, Issue 4, 2016, Pages 613-622

  Thomopoulos, Costas ^a   Parati, Gianfranco ^b,c   Zanchetti, Alberto ^d  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

antihypertensive treatment; hypertension; intense antihypertensive treatment; meta analysis; randomized controlled trials; target blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DIASTOLIC BLOOD PRESSURE; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INTENSIVE CARE; ISCHEMIC HEART DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREHYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; INCIDENCE; TREATMENT OUTCOME;

EID: 84960411883     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000881     Document Type: Review

References (63)

1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285-2295.
2. Hansson L. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-Effects, morbidity and mortality in ?well treated? hypertensive patients. Behandla Blodtryck Bättre. Blood Press 1994; 3:248-254.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-Dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
5. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-Term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142:342-351.
6. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23:B54-B64.
7. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
8. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:1042-1049.
9. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005; 365:939-946.
10. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115-2127.
11. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678-1689.
12. Verdecchia P, Staessen JA, Angeli F, De Simone G, Achilli A, Ganau A, et al. Usual vs. tight control of systolic blood pressure in nondiabetic patients with hypertension (Cardio-Sis): an open-label randomized trial. Lancet 2009; 374:525-533.
13. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
14. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56:196-202.
15. SPS3 Study Group BenaventeOR, Coffey CS, Conwit R, Hart RG,McClure LA, Pearce LA, et al. . Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382:507-515.
16. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
17. Blood Pressure Lowering Treatment Trialists? Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively- designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
18. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665; doi: 10.1136/bmj.b1665.
19. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-Analysis. Lancet 2015; doi: 10.1016/S0140-6736(15)00805-3.
20. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-2116.
21. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
22. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 2. Effects at different baseline and achieved blood pressure levels. Overview and metaanalyses of randomized trials. J Hypertens 2014; 32:2296-2304.
23. Moher D, Liberati A, Tetzlaff J. Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ 2009; 339:b2535; doi: 10.1136/bmj.b2535.
24. Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens 2013; 15:420-427.
25. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
26. Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006; 19:1241-1248.
27. Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639-1650.
28. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-Dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13:1733-1739.
29. Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res 2012; 35:1102-1110.
30. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. Strict? blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48:851-859.
31. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack, the PAST-BP (Prevention After Stroke-Blood Pressure) study: randomised controlled trial. https:// www.repository.cam.ac.uk/handle/1810/253061.
32. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment. 6. Prevention of heart failure and new onset heart failure. Meta-Analysis of randomized trials. J Hypertens 2016; 34:373-384.
33. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 3. Effects in patients at different levels of cardiovascular risk. Overview and meta-Analyses of randomized trials. J Hypertens 2014; 32:2305-2314.
34. Amery A, Brixko P, Clement D, De Schaepdryver A, Fagard R, Forte J, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 325:1349-1354.
35. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229:409-418.
36. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
37. Perry HM Jr, Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke 1989; 20:4-13.
38. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
39. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129mm Hg. JAMA 1967; 202:1028-1034.
40. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 37:829-840.
41. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-Term placebo controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172.
42. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242:2562-2571.
43. Medical Research Council Working Party. MRC trial on treatment of mild hypertension: principal results. BMJ 1985; 291:97-104.
44. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980; 69:725-732.
45. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
46. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977; 40:I98-105.
47. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 90 through 114mm Hg. JAMA 1970; 213:1143-1152.
48. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-Enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
49. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
50. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
51. Davis BR, Ford CE. The Hypertension Detection Follow-up Program. In: Black HR, editor. Clinical trials in hypertension. New York: Marcel Dekker, Inc; 2001. pp. 7-60.
52. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713-724.
53. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31:1007-1014.
54. The PEACE Trial Investigators. Angiotensin-converting-Enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
55. Blood Pressure Lowering Treatment Trialists? Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a metaanalysis of individual patient data. Lancet 2014; 384:591-598.
56. Brunström M, Carlberg B. Lower blood pressure targets: to whom do they apply? Lancet 2015; doi: 10.1016/S0140-6736(15)00816-8.
57. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and low-Density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens 2014; 32:1741-1750.
58. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-1357.
59. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
60. Weber MA, Schiffrin EL, White B, Mann S, Lindholm L, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15.
61. Zanchetti A. Hypertension meta-Analyses: first rank evidence or second hand information? Nat Rev Cardiol 2011; 8:249-251.
62. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. Rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens 2016; 34:393-396.
63. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens 2014; 32:1888-1897.